ETR:AFX Carl Zeiss Meditec (AFX) Stock Price, News & Analysis €46.26 -2.38 (-4.89%) As of 08/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Carl Zeiss Meditec Stock (ETR:AFX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Carl Zeiss Meditec alerts:Sign Up Key Stats Today's Range€46.26▼€48.3250-Day Range€48.64▼€62.9552-Week Range€54.60▼€123.75Volume200,321 shsAverage Volume94,405 shsMarket Capitalization€4.31 billionP/E Ratio24.72Dividend Yield2.38%Price TargetN/AConsensus RatingN/A Company Overview Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG. Read More Receive AFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter. Email Address AFX Stock News HeadlinesCarl Zeiss Meditec (ETR:AFX) shareholders have endured a 62% loss from investing in the stock three years agoJuly 21, 2025 | uk.finance.yahoo.comCarl Zeiss Meditec AG (AFX) Stock Price Today - WSJJuly 1, 2025 | wsj.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027EJune 8, 2025 | seekingalpha.comCarl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comEQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25April 15, 2025 | markets.businessinsider.comCarl Zeiss Meditec AG: ZEISS receives FDA clearance for INTRABEAM 700April 9, 2025 | finanznachrichten.deCarl Zeiss Meditec's (ETR:AFX) Dividend Will Be Reduced To €0.60March 22, 2025 | finance.yahoo.comSee More Headlines AFX Stock Analysis - Frequently Asked Questions How have AFX shares performed this year? Carl Zeiss Meditec's stock was trading at €45.52 at the start of the year. Since then, AFX stock has increased by 1.6% and is now trading at €46.26. What other stocks do shareholders of Carl Zeiss Meditec own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carl Zeiss Meditec investors own include Intel (INTC), Meta Platforms (META), NVIDIA (NVDA), Volkswagen (VOW3), AbbVie (ABBV), Chevron (CVX) and Siemens Aktiengesellschaft (SIE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolETR:AFX CIKN/A Webwww.zeiss.com Phone+49-3641-2200FaxN/AEmployees4,950Year FoundedN/AProfitability EPS (Trailing Twelve Months)€1.87 Trailing P/E Ratio24.72 Forward P/E Ratio15.84 P/E Growth2.83Net Income€185.59 million Net Margins7.03% Pretax MarginN/A Return on Equity8.49% Return on Assets7.03% Debt Debt-to-Equity Ratio7.41 Current Ratio2.13 Quick Ratio2.47 Sales & Book Value Annual Sales€2.64 billion Price / Sales1.63 Cash Flow€0.03 per share Price / Cash Flow1,398.28 Book Value€22.92 per share Price / Book2.02Miscellaneous Outstanding Shares93,178,085Free FloatN/AMarket Cap€4.31 billion OptionableNot Optionable Beta0.98 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (ETR:AFX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carl Zeiss Meditec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Carl Zeiss Meditec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.